Waters to open laboratory with Chinese Pharmacopoeia

By Zachary Brennan contact

- Last updated on GMT

Both the ChP and Waters expect the lab to become one of the national technical support centers in the field of Chinese pharmaceutical standards
Both the ChP and Waters expect the lab to become one of the national technical support centers in the field of Chinese pharmaceutical standards

Related tags: Mass spectrometry

Pharma technology provider Waters as agreed with the Chinese Pharmacopoeia Commission (ChP) to establish a joint open laboratory to develop new pharmacopoeia standards.

Scheduled to open before the end of 2014, the new 1,400 square foot lab will focus on the research of pharmacopoeia standards, development of testing methods, methods validations and basic and advanced technical training of pharmacopoeia detection methods. The lab will be outfitted with Waters chromatography and mass spectrometry technologies, including a range of Acquity UPLC systems, Acquity UPC System, Xevo tandem quadrupole and time-of-flight mass spectrometers, and a Natural Products ​Application Solution with ​UNIFI.

Both the ChP and Waters expect the lab to become one of the national technical support centers in the field of Chinese pharmaceutical standards.

ChP has developed methodologies for a wide range of drugs and pharmaceuticals and now the desire and drive is to develop more of a library for natural products and traditional Chinese medicine, Waters spokesman Jeff Tarmy told us. “They have thousands of years of experience with these products and they’re looking to create standards for those active ingredients​.”

Waters’ past work with the USP (US Pharmacopoeia), as well as its work helping companies develop testing methods should be a boon for the company’s efforts in China, Tarmy said.

At the collaboration agreement signing ceremony in Beijing, Secretary General Zhang Wei of the ChP pointed out that "the ChP-Waters Joint Open Laboratory cooperation would become another milestone of the development of the ChP. This cooperation not only meets the needs of ChP’s own development, but also meets the demands of enhanced pharmacopoeia standards and improved public drug safety.”

Art Caputo, President of the Waters Division, added: "I am confident that this new Joint Open Laboratory will make positive contributions to assuring drug quality control in China, it will quickly become an international leader in the field of traditional Chinese pharmaceutical standards​."

Related news

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars